Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleBasic Science Investigation

Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting

Roland Haubner, Hans-Jürgen Wester, Ute Reuning, Reingard Senekowitsch-Schmidtke, Beate Diefenbach, Horst Kessler, Gerhard Stöcklin and Markus Schwaiger
Journal of Nuclear Medicine June 1999, 40 (6) 1061-1071;
Roland Haubner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Jürgen Wester
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ute Reuning
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reingard Senekowitsch-Schmidtke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beate Diefenbach
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Horst Kessler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerhard Stöcklin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Schwaiger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 40 no. 6 1061-1071
PubMed 
10452325

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X

Copyright & Usage 
COPYRIGHT© 1999 by the Society of Nuclear Medicine, Inc.

Author Information

Statistics from Altmetric.com

Cited By...

  • 373 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: February 2001 to April 2025

AbstractFullPdf
Feb 2001300
Mar 2001200
Apr 20011000
May 2001700
Jun 2001600
Jul 2001200
Aug 2001600
Sep 2001800
Oct 2001401
Nov 2001300
Dec 2001202
Jan 2002501
Feb 2002405
Mar 2002502
Apr 2002904
May 2002200
Jun 2002703
Jul 20021008
Aug 2002202
Sep 2002705
Oct 2002503
Nov 20026010
Dec 2002500
Jan 2003609
Feb 2003708
Mar 2003504
Apr 2003405
May 2003704
Jun 20031205
Jul 20031708
Aug 20031103
Sep 20032607
Oct 20032309
Nov 20032709
Dec 200323013
Jan 20041806
Feb 20041905
Mar 20042608
Apr 200420010
May 20041907
Jun 20043008
Jul 20043201
Aug 200414011
Sep 20042304
Oct 200426019
Nov 200426020
Dec 200423011
Jan 200529014
Feb 200533010
Mar 200534019
Apr 20051409
May 20051107
Jun 20051107
Jul 2005702
Aug 2005706
Sep 200518012
Oct 200510011
Nov 200516011
Dec 20051609
Jan 20061204
Feb 20061201
Mar 2006703
Apr 20061109
May 20061308
Jun 20068011
Jul 2006807
Aug 200610016
Sep 200619020
Oct 20061006
Nov 2006905
Jan 200711030
Feb 20076028
Mar 20075018
Apr 200713018
May 200718040
Jun 200710039
Jul 200712026
Aug 200712025
Sep 200713016
Oct 200718046
Nov 20076029
Dec 20079011
Jan 200816034
Feb 200814030
Mar 200814036
Apr 20089036
May 200890032
Jun 2008242043
Jul 200844033
Aug 200817035
Sep 200826036
Oct 20089027
Nov 20089025
Dec 20085015
Jan 200911021
Feb 200913033
Mar 200912024
Apr 200911026
May 200913024
Jun 200913030
Jul 20098027
Aug 20096021
Sep 200915080
Oct 20099034
Nov 200918036
Dec 200920025
Jan 201011038
Feb 20101026
Mar 201012024
Apr 201010020
May 201012034
Jun 201018042
Jul 201014025
Aug 20109026
Sep 201015024
Oct 201016032
Nov 20109016
Dec 201017025
Jan 201115052
Feb 201115027
Mar 201117032
Apr 201132038
May 201114024
Jun 20110041
Jul 20110030
Aug 20110242
Sep 20110033
Oct 20110022
Nov 20110049
Dec 20110026
Jan 20120024
Feb 20120127
Mar 20120025
Apr 20120129
May 20120147
Jun 20120037
Jul 20120030
Aug 20120021
Sep 20120034
Oct 20120017
Nov 20120022
Dec 20120015
Jan 2013002157
Feb 20130099
Mar 20130083
Apr 20130026
May 20130071
Jun 20130010
Jul 20130018
Aug 20130012
Sep 20130014
Oct 20130020
Nov 20130011
Dec 20130025
Jan 20140021
Feb 20140015
Mar 20140032
Apr 20140013
May 20140022
Jun 20140022
Jul 20140013
Aug 20140018
Sep 20140017
Oct 20140025
Nov 20140015
Dec 20140015
Jan 20150022
Feb 20150123
Mar 20150026
Apr 20150323
May 20150090
Jun 20150014
Jul 20150028
Aug 2015008
Sep 20150013
Oct 20150014
Nov 20150018
Dec 20150023
Jan 20160046
Feb 20160020
Mar 20160014
Apr 20160016
May 20160020
Jun 20160020
Jul 20160014
Aug 20160036
Sep 20160123
Oct 20160025
Nov 20160121
Dec 2016008
Jan 20170022
Feb 20170014
Mar 20170017
Apr 2017007
May 20170014
Jun 20170019
Jul 2017009
Aug 20170011
Sep 20170013
Oct 20170023
Nov 20170022
Dec 20170023
Jan 20180025
Feb 20180015
Mar 20180031
Apr 20180021
May 20180022
Jun 20180016
Jul 20180018
Aug 20180013
Sep 20180010
Oct 20180011
Nov 20180021
Dec 2018004
Jan 2019008
Feb 20190019
Mar 2019005
Apr 20190011
May 20190020
Jun 20190010
Jul 20190020
Aug 20190018
Sep 20190014
Oct 20190047
Nov 20190031
Dec 20190034
Jan 20200028
Feb 20200017
Mar 20200035
Apr 20200020
May 20200025
Jun 20200021
Jul 2020007
Aug 20200013
Sep 20200015
Oct 20200021
Nov 20200026
Dec 20200020
Jan 20212018
Feb 20210026
Mar 20210020
Apr 20210024
May 20210022
Jun 20211013
Jul 20211019
Aug 20210018
Sep 20210019
Oct 20210012
Nov 20210024
Dec 20211014
Jan 20220016
Feb 20221010
Mar 20220018
Apr 20221010
May 20220022
Jun 20221033
Jul 20221028
Aug 20220027
Sep 20221011
Oct 20220020
Nov 20220012
Dec 20221011
Jan 2023007
Feb 2023005
Mar 2023007
Apr 20231010
May 2023206
Jun 2023104
Jul 2023007
Aug 20230010
Sep 2023001
Oct 2023203
Nov 2023004
Dec 20232014
Jan 20240013
Feb 2024305
Mar 2024007
Apr 20240021
May 2024006
Jun 2024009
Jul 2024109
Aug 20241011
Sep 20240011
Oct 2024108
Nov 2024108
Dec 20240013
Jan 20251020
Feb 2025008
Mar 20252012
Apr 20250021
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 40, Issue 6
June 1, 1999
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Advertising (PDF)
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting
Roland Haubner, Hans-Jürgen Wester, Ute Reuning, Reingard Senekowitsch-Schmidtke, Beate Diefenbach, Horst Kessler, Gerhard Stöcklin, Markus Schwaiger
Journal of Nuclear Medicine Jun 1999, 40 (6) 1061-1071;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting
Roland Haubner, Hans-Jürgen Wester, Ute Reuning, Reingard Senekowitsch-Schmidtke, Beate Diefenbach, Horst Kessler, Gerhard Stöcklin, Markus Schwaiger
Journal of Nuclear Medicine Jun 1999, 40 (6) 1061-1071;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Complementary, Selective PET Imaging of Integrin Subtypes {alpha}5{beta}1 and {alpha}v{beta}3 Using 68Ga-Aquibeprin and 68Ga-Avebetrin
  • 99mTc-3PRGD2 for Integrin Receptor Imaging of Lung Cancer: A Multicenter Study
  • Effects of Photoacoustic Imaging and Photothermal Ablation Therapy Mediated by Targeted Hollow Gold Nanospheres in an Orthotopic Mouse Xenograft Model of Glioma
  • Fluorescence Reflectance Imaging of Macrophage-Rich Atherosclerotic Plaques Using an {alpha}v{beta}3 Integrin-Targeted Fluorochrome
  • Radionuclide Imaging: A Molecular Key to the Atherosclerotic Plaque
  • Preparation of a Promising Angiogenesis PET Imaging Agent: 68Ga-Labeled c(RGDyK)-Isothiocyanatobenzyl-1,4,7-Triazacyclononane-1,4,7-Triacetic Acid and Feasibility Studies in Mice
  • Intratumoral Spatial Distribution of Hypoxia and Angiogenesis Assessed by 18F-FAZA and 125I-Gluco-RGD Autoradiography
  • Correlative Imaging of Hypoxia and Angiogenesis in Oncology
  • Integrin {alpha}V{beta}3 Binds to the RGD Motif of Glycoprotein B of Kaposi's Sarcoma-Associated Herpesvirus and Functions as an RGD-Dependent Entry Receptor
  • Noninvasive Imaging of Osteoclasts in Parathyroid Hormone-Induced Osteolysis Using a 64Cu-Labeled RGD Peptide
  • Favorable Biokinetic and Tumor-Targeting Properties of 99mTc-Labeled Glucosamino RGD and Effect of Paclitaxel Therapy
  • How molecular imaging is speeding up antiangiogenic drug development
  • In vitro and In vivo Characterization of 64Cu-Labeled AbegrinTM, a Humanized Monoclonal Antibody against Integrin {alpha}v{beta}3
  • Positron Emission Tomography As an Imaging Biomarker
  • PET-Based Human Dosimetry of 18F-Galacto-RGD, a New Radiotracer for Imaging {alpha}v{beta}3 Expression
  • Quantitative PET Imaging of Tumor Integrin {alpha}v{beta}3 Expression with 18F-FRGD2
  • Molecular Targeting with Peptides or Peptide-Polymer Conjugates: Just a Question of Size?
  • Targeting Tumor Angiogenesis: Comparison of Peptide and Polymer-Peptide Conjugates
  • Radiolabeled RGD Uptake and {alpha}v Integrin Expression Is Enhanced in Ischemic Murine Hindlimbs
  • Induction of Apoptosis with Hybrids of Arg-Gly-Asp Molecules and Peptides and Antimitotic Effects of Hybrids of Cytostatic Drugs and Peptides
  • Radiolabeled RGD Peptides Move Beyond Cancer: PET Imaging of Delayed-Type Hypersensitivity Reaction
  • Detection of Injury-Induced Vascular Remodeling by Targeting Activated {alpha}v{beta}3 Integrin In Vivo
  • Oncological molecular imaging: nuclear medicine techniques
  • Signaling through JAM-1 and {alpha}v{beta}3 is required for the angiogenic action of bFGF: dissociation of the JAM-1 and {alpha}v{beta}3 complex
  • Tumor Targeting with Radiolabeled {alpha}v{beta}3 Integrin Binding Peptides in a Nude Mouse Model
  • Arginine-Glycine-Aspartic Acid (RGD)-Peptide Binds to Both Tumor and Tumor-Endothelial Cells in Vivo
  • Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies
  • Cilengitide Targeting of {alpha}v{beta}3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts
  • Noninvasive Imaging of {{alpha}}v{beta}3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography
  • Glycosylated RGD-Containing Peptides: Tracer for Tumor Targeting and Angiogenesis Imaging with Improved Biokinetics
  • Google Scholar

More in this TOC Section

  • Establishing In Vitro Dosimetric Models and Dose–Effect Relationships for 177Lu-DOTATATE in Neuroendocrine Tumors
  • Designed Ankyrin Repeat Protein–Mediated Peptide Nucleic Acid–Based Pretargeting: A Proof-of-Principle Study
  • [11C]ZTP-1: An Effective Short-Lived Radioligand for PET of Rat and Monkey Brain Phosphodiesterase Type 4 Subtype B
Show more Basic Science Investigation

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire